Publications
Publications
- 2020
- HBS Working Paper Series
Chimeric Antigen Receptor (CAR) T-Cell Therapy: Case Histories of Significant Medical Advances
By: Amar Bhidé and Srikant M. Datar
Abstract
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works; 2) the foundational advances and discoveries; 3) development of CAR-T therapy; and 4) the situation in 2019.
Keywords
Immunotherapy; Health Care and Treatment; Innovation and Invention; Research and Development; Governing Rules, Regulations, and Reforms
Citation
Bhidé, Amar, and Srikant M. Datar. "Chimeric Antigen Receptor (CAR) T-Cell Therapy: Case Histories of Significant Medical Advances." Harvard Business School Working Paper, No. 21-034, August 2020.
About The Authors
